

Preparing Triple-Compound Heterozygous Control Material for Molecular Diagnostics of *TPMT* Allelic Variants

(thiopurine S-methyltransferase / gene synthesis / reference material / commutability / heterozygosity)

M. BERÁNEK^{1,3}, M. DRASTÍKOVÁ¹, J. BUREŠ², V. PALIČKA¹

¹Institute of Clinical Biochemistry and Diagnostics, ²2nd Department of Internal Medicine, Faculty of Medicine in Hradec Králové, ³Faculty of Pharmacy in Hradec Králové, Charles University in Prague and University Hospital Hradec Králové, Czech Republic

Abstract. The aim of the study is to present a novel approach for preparing triple-compound heterozygous reference material (TCH-RM) for thiopurine S-methyltransferase (*TPMT*) genotyping by using the gene synthesis technology. The polynucleotide chain we prepared consisted of three wild-type and three mutant segments corresponding to the *TPMT* 238G>C, 460G>A, and 719A>G polymorphic sites. TCH-RM characteristics were assessed via four methods: reverse hybridization, real-time PCR with hydrolysis probes, real-time PCR followed by subsequent melting temperature analysis, and DNA sequencing. Consequently, we investigated the *TPMT* genotype of 371 patients suffering from autoimmune diseases requiring immunosuppressive therapy with thiopurine drugs, mostly inflammatory bowel disease. All methods confirmed the triple heterozygous character and commutability of TCH-RM. In evaluating its stability we obtained very comparable data before and after six months of storage at -80 °C. The determined genotypes were as follows: 352 wild-type subjects (94.8 %), 17 *TPMT**3A heterozygotes (460G>A and 719A>G, 4.6 %), one patient heterozygous for the *TPMT**2 allele (238G>C, 0.3 %), and one *TPMT**3C heterozygote (719A>G, 0.3 %). The frequencies of *TPMT**1, *3A, *3C, and *2 in the pa-

tients were 97.5 %, 2.3 %, 0.1 %, and 0.1 %, respectively. Assembling segments of synthetic DNA into long polynucleotide chains is a universal way of obtaining compound heterozygous material for performing any simultaneous analysis of polymorphic sites in the human genome. The batches are manufactured with a perfect concentration match of wild-type and mutant fragments, and can be made in large quantities for most diagnostic techniques.

Introduction

Thiopurine S-methyltransferase (EC 2.1.1.67, *TPMT*) is a cytosolic enzyme catalysing the S-methylation of thiopurine drugs (azathioprine, 6-mercaptopurine, 6-thioguanine). It is encoded by a 27 kb gene located on chromosome 6p22.3. Depending on the ethnicity, either low or intermediate *TPMT* activity was found in 5–11 % of the population (Gearry and Barclay, 2005), indicating hereditary polymorphism in the *TPMT* gene in humans. The wild-type *TPMT* allele was designated *TPMT**1. The most frequent allelic variants associated with the altered enzyme activity are: *TPMT**2 (c.238G>C, rs1800462), *TPMT**3B (c.460G>A, rs1800460), *TPMT**3C (c.719A>G, rs1142345), and *TPMT**3A (c.460G>A and c.719A>G).

All the minor variants in the *TPMT* gene are considered to slow down the metabolism of thiopurine drugs in the body. *TPMT* enzymes encoded by these alleles have a significantly shorter half-life than the wild-type (Krynetski and Evans, 1999). The lower cellular levels observed are caused by enhanced proteasomal degradation of misfolded mutant *TPMT* (Tai et al., 1997).

Genetic testing applied prior to the first administration of thiopurines allows identification of up to 98 % of slow drug metabolizers (Yates et al., 1997). Moreover, it prevents drugs overdose and reduces the risk of developing severe myelosuppression, hepatic toxicity, pancreatitis, mucositis, or dermatological problems. Numerous methods have been previously used for *TPMT* genotyping, including restriction analysis (Yates et al., 1997), multiplex amplification refractory mutation sys-

Received March 16, 2015. Accepted April 15, 2015.

The study was supported by grant SVV 260057/2014, and by project PRVOUK P37 of Charles University in Prague, Czech Republic.

Corresponding author: Martin Beránek, Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Králové, Charles University in Prague and University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec Králové. Phone: (+420) 495 833 040; Fax: (+420) 495 832 003; e-mail: beranek@lfhk.cuni.cz

Abbreviations: Ct – cycle thresholds, CV – coefficients of variation, RM – reference control materials, TCH-RM – triple-compound heterozygous reference control material, *TPMT* – thiopurine S-methyltransferase.

tems (Roberts et al., 2004), single-strand conformational polymorphism (Spire-Vayron de la Moureyre et al., 1998a), real-time PCR (Schutz et al., 2000), reverse hybridization strips (Fakhoury et al., 2007), pyrosequencing (Haglund et al., 2004), and microarray technology (Soltysova et al., 2011).

The analytical accuracy and reliability of *TPMT* genotyping are commonly ensured by using reference control materials (RM) based on genomic DNA (Spire-Vayron de la Moureyre et al., 1998b), recombinant DNA molecules obtained by targeted mutagenesis (Burchard et al., 2014), or synthetically manufactured materials (Chen et al., 2014). In genotyping assays for rare variants, i.e. *TPMT*2* or *TPMT*3B*, heterozygous controls are prepared by mixing wild-type and mutant DNA fragments/clones in equal concentrations. The mixing ratio is usually determined by measuring the optical density or fluorescence of intercalating dyes. However, the imprecision of these methods can create a disproportionate amount of wild-type and mutant DNA molecules in the mixture. Moreover, the ratios are only valid for the tested batches of RMs.

The aim of this study is to present a novel approach for preparing triple-compound heterozygous reference control material (TCH-RM) for *TPMT* genetic testing by using the technology of hybrid gene synthesis (Hughes et al., 2011) with the insertion of wild-type and mutant polynucleotide fragments into a single cloning vector.

Material and Methods

Subjects

We investigated 371 patients (132 men and 239 women, median age 45 years, range 18–84 years) at the Charles University Hospital in Hradec Kralove, who were suffering from inflammatory bowel disease, autoimmune hepatitis, systemic lupus erythematosus, idiopathic inflammatory myopathies, multiple sclerosis or rheumatoid arthritis. Genotyping was performed with the informed consent of the patients prior to the first administration of thiopurine drugs. Genomic DNA was extracted from 200 μ l of blood using a QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany).

Preparation of TCH-RM

The synthesized 2446 bp polynucleotide chain (GenScript, Piscataway, NJ) contained six *TPMT* gene segments in lengths sufficient for reliable laboratory testing. The segments were aligned in the following order (Fig. 1): *TPMT 238G* wild-type (segment I; 510 bp; NCBI reference sequence code NC_000006.12; positions 15560–15051), *460G* wild-type (segment II; 292 bp; positions 10889–10598), *719A* wild-type (segment III; 421 bp; positions 2535–2115), *238C* mutant (segment IV; 510 bp; positions 15051–15560), *460A* mutant (segment V; 292 bp; positions 10598–10889), and *719G* mutant (segment VI; 421 bp; positions 2115–2535). The




Fig. 1. Structure of a pUC57 vector containing six synthetic segments of the *TPMT* gene. Segments I and IV include a nucleotide sequence specific for *TPMT 238G>C* polymorphism; segments II and V for *460G>A*; and segments III and VI for *719A>G*. Segments I-III are wild-type sequences, segments IV-VI contain mutant sequences.

complete chain was inserted into a pUC57 cloning vector; the constructs were transferred into an *E. coli* competent strain and amplified (GenScript). This was followed by purification, spectrophotometric determination of plasmid DNA concentration, and freeze-drying. After reconstituting the freeze-dried DNA molecules in Tris-EDTA buffer, serial dilution (10^9 – 10^1 copies/ μ l) in plastic tubes was performed. Aliquots of 20 μ l diluted DNA were stored at -80 °C. TCH-RM characteristics were assessed via four various methods: reverse hybridization, real-time PCR with hydrolysis probes, real-time PCR followed by subsequent melting temperature analysis, and dideoxynucleotide DNA sequencing.

Reverse hybridization assay

TCH-RM at a concentration of 10^5 copies/ μ l was used for multiplex PCR with biotinylated primers and reverse hybridization on nitrocellulose strips according to the manufacturer's instructions (PGX-TPMT StripAssay Kit, ViennaLab, Vienna, Austria). The lengths of the PCR products were 137 bp (*TPMT*2*), 165 bp (*TPMT*3B*), and 255 bp (*TPMT*3C*).

Real-time PCR assays

Real-time PCR with melting temperature analysis was performed in the LightCycler 2.0 (Roche Diagnostics, Penzberg, Germany) using LightSNiP hu *TPMT*2* rs1800462, LightSNiP hu *TPMT*3B* rs1800460, and LightSNiP hu *TPMT*3C* rs1142345 assays with minor modifications (Pozler et al., 2010) of the conditions specified by the manufacturer (TIB MolBiol, Berlin, Germany). Allelic discrimination assays using real-time PCR with fluorescent hydrolysis probes (Yi *TPMT* Kit, Ybux, Brno, Czech Republic) for c.238G>C, c.460G>A, and c.719A>G *TPMT* polymorphisms were carried out in a Rotorgene 6000 (Corbett Research, Sydney, Australia) following the manufacturer's protocol.

DNA sequencing

PCR amplicons were generated in mixtures (25 μ l) containing $10\times$ concentrated PCR buffer, 200 mM each of deoxynucleotides, 400 nM primers (Generi Biotech, Hradec Králové, Czech Republic), 2.5 mM magnesium chloride, 50 ng of DNA, and one unit of *Taq* polymerase HS (Takara, Shiga, Japan). The following sequences of forward and reverse primers were used: 5'- CCT GCA TGT TCT TTG AAA CCC TAT GAA -3' and 5'- GCT TGA GTA CAG AGA GGC TTT GAC CTC -3' for *TPMT*2*; 5'- CTC CAC ACC CAG GTC CAC ACA TT -3' and 5'- GTA TAG TAT ACT AAA AAA TTA AGA CAG CTA AAC -3' for *TPMT*3B*; and 5'- AAT CCC TGA TGT CAT TCT TCA TAG T -3' and 5'- CAC ATC ATA ATC TCC TCT CC -3' for *TPMT*3C* analysis. After initial denaturation (5 min at 95 °C), PCRs were run for 35 cycles consisting of 40 s denaturation at 95 °C, 40 s annealing at 55 °C, and 60 s extension at 72 °C in the ABI 2720 thermal cyler (Life Technologies, Carlsbad, CA). The sizes of the amplicons for c.238G>C,

c.460G>A, and c.719A>G were 510 bp, 292 bp, and 421 bp, respectively. The same primers were used for bidirectional sequencing with a BigDye Terminator v3.1 Cycle Sequencing Kit and the ABI 3130 Genetic Analyzer (Life Technologies). Unincorporated dye terminators, salts, and unused primers were removed by the Biomek 4000 Automated Laboratory Workstation (Beckman Coulter, Fullerton, CA).

Testing TCH-RM stability

The storage stability of DNA molecules in the TCH-RM aliquots containing 10^6 copies/ μ l was examined using real-time PCR (Yi *TPMT* Kit) under the same conditions as above. Differences in cycle thresholds (Ct) were evaluated after six months of storage. The storage period was interrupted six times by thawing the tubes to room temperature for 30 min.

Statistical analysis

All experiments were done in triplicates. Calculations of means, standard deviations, coefficients of variation (CV), and mean differences were performed using the Statistica software (version 11, StatSoft, Tulsa, OK) for Windows.

Results

The triple heterozygous character of TCH-RM was shown by the presence of six bands specific for wild-type and mutant *TPMT* alleles on the hybridization test strips (Fig. 2a). Their intensities corresponded well to the results from the heterozygous subjects (Figs. 2b, 2c). TCH-RM triple-compound heterozygosity was further verified by dideoxynucleotide sequencing analysis. The electropherograms showed typical double peaks visible in all the polymorphic sites (Fig. 3).

The results of the melting temperature analysis of TCH-RM for c.238G>C, c.460G>A, and c.719A>G polymorphisms are presented in Fig. 4. Melting temperatures for the tested allelic variants were as follows: 54 °C for the 238G wild-type allele, 64 °C for 238C, 53 °C for




Fig. 2. Reverse hybridization analysis of the *TPMT* gene. Strip a: synthetic triple-compound heterozygous reference material; strip b: 238G>C heterozygous patient (genotype *2/*1); strip c: 460G>A and 719A>G heterozygous patient (genotype *3A/*1).




Fig. 3. Results of dideoxynucleotide sequencing analysis of TCH-RM. Its triple heterozygosity for 238G>C (left part), 460G>A (middle part), and 719A>G (right part) mutations is demonstrated.




Fig. 4. Melting temperature analysis of TCH-RM heterozygosity. Front curve: *TPMT* 238G>C polymorphism (wild-type allele 54 °C, 238C allele 64 °C); middle curve: 460G>A (wild-type allele 53 °C, 460A allele 59 °C); back curve: 719A>G (wild-type allele 51 °C, 719G allele 58 °C).




Fig. 5. Allelic discrimination real-time PCR revealing TCH-RM heterozygosity for 238G>C. Solid lines manifest PCR amplification of 238G wild-type allele, broken lines present 238C allele. Lines *a*: TCH-RM at a concentration of 10^6 copies/ μ l; lines *b*: 10^5 copies/ μ l; lines *c*: 10^4 copies/ μ l; lines *d*: 10^3 copies/ μ l; lines *e*: 10^2 copies/ μ l.

Table 1. Stability of TCH-RM analysed by real-time PCR cycle threshold (Ct)

Assay	Allele	Ct Values		
		Day 0	Day +180	Δ Ct
TPMT 238G>C	238G (*1)	20.4 (0.2)	21.1 (0.2)	0.7
	238C (*2)	20.0 (0.3)	19.9 (0.3)	-0.1
TPMT 460G>A	460G (*1)	19.3 (0.6)	19.8 (0.3)	0.5
	460A (*3B)	18.9 (0.4)	18.9 (0.4)	0.0
TPMT 719A>G	719A (*1)	21.4 (0.1)	21.9 (0.2)	0.5
	719G (*3C)	22.3 (0.1)	21.5 (0.2)	-0.8

Values are expressed as means (standard deviations) of triplicates and mean differences (Δ Ct); *1, *2, *3B, *3C are tested *TPMT* alleles.

460G wild-type, 59 °C for 460A, 51 °C for 719A wild-type, 58 °C for 719G. Also, allelic discrimination real-time PCR confirmed its triple heterozygous character and a high degree of commutability in the range of five concentration orders (from 10^2 to 10^6 copies/ μ l), as demonstrated in Fig. 5.

Table 1 indicates Ct values of triplicates observed in allelic discrimination real-time PCR. The differences between the mutant and wild-type *TPMT* fragments of all three studied polymorphisms were less than 1.1 cycle if a threshold of 0.05 was chosen. When we evaluated the stability of the frozen TCH-RM aliquots via real-time PCR quantification, we achieved highly concordant triplicate data with coefficients of variability lower than 4 % for all three assays. The differences in mean Ct values (Δ Ct) before and after six months of storage were lower than one amplification cycle.

The determined genotypes of the patients were as follows: 352 wild-type subjects (94.8 %), 17 *TPMT**3A heterozygotes (4.6 %), one patient heterozygous for the *TPMT**2 allele (0.3 %), and one *TPMT**3C heterozygote (0.3 %). No other *TPMT* genotype was found. The frequencies of *TPMT**1, *3A, *3C, and *2 in the entire cohort were 97.5 %, 2.3 %, 0.1 %, and 0.1 %, respectively.

Discussion

TPMT genotyping is one of the most basic pharmacogenetic markers. Results of the analysis must be available prior to starting thiopurine drug therapy, and for such analysis simple, rapid, and reliable assays based on real-time PCR are currently preferred (Roman et al., 2012; Burchard et al., 2014; Chen et al., 2014).

Each experimental run performed in clinical labs should include control samples whose results support the validity of the analytical processes used. Homozygous controls are usually made by mixing either wild-type or mutant DNA fragments associated with the polymorphic sites tested. However, preparing a multi-allelic heterozygous RM for molecular diagnostics is made complicated by i) discrepancies in amplification efficiencies between site-specific wild-type and mutant DNA frag-

ments, ii) the varying quality, purity, and stability of the fragments, and iii) imprecision in determining the concentrations of wild-type and mutant fragments in the final mixture.

We suggest a unique RM consisting of six polynucleotide segments forming a *TPMT* 238G>C/460G>A/719A>G triple-compound heterozygous genotype. Due to the almost complete homogeneity of the appropriate pairs of wild-type and mutant segments differing in one nucleotide only, assembling them into direct tandems during the synthesis was impossible (Beranek et al., 2014). Therefore, we used an alignment of the segments according to the absence/presence of the mutation: the first three segments contained parts of the coding sequence of the *TPMT*1* close to c.238G>C, c.460G>A, and c.719A>G polymorphic sites; the second three contained the nucleotide sequences of the *TPMT*2*, **3B*, and **3C* allelic variants.

The lengths of the segments were selected to reach a high degree of commutability for the various analytical techniques. Similar ranges of synthetic polynucleotides are currently used when preparing control materials for *TPMT* genotyping in a traditional manner (Burchard et al., 2014).

The nucleotide sequences within the segments contained several other polymorphic sites that only rarely influence the enzymatic activity of *TPMT* in the population (Zhou and Chowbay, 2007): **3D* (G292T) and **19* (A365C) in segments I and III; **10* (G430C), **15* (IVS-1G>A), **16* (G488A), and **22* (G488C) in segments II and IV; and **7* (T681G) and **8* (G644A) in segments III and VI. The sequencing analysis performed was able to confirm the wild-type character of TCH-RM in these sites.

All the testing methods yielded concordant results of TCH-RM analysis, thus showing its compound heterozygosity, universality, and commutability. Concentrations of TCH-RM ranging from 10^4 to 10^5 copies/ μ l provided amplification curves comparable with those obtained for human DNA extracted from blood or buccal swabs. No signs of degradation during the storage of TCH-RM at -80 °C were recorded. Therefore, the properties of our multi-allelic RM support its availability for real-time PCR amplification, especially if the *TPMT* polymorphisms are tested simultaneously in one experimental run.

Using TCH-RM, we identified 19 *TPMT* heterozygotes in the group of patients. The frequencies of *TPMT* genotypes and allelic variants were in agreement with previous studies performed on Caucasians (Ameyaw et al., 1999; Haglund et al., 2004; Geary and Barclay, 2005; Almoguera et al., 2014). All the heterozygotes expressing intermediate *TPMT* activity were treated with thiopurines, a process that started with a reduced dose and increased incrementally to a target weight-based dose according to recent guidelines (Relling et al., 2013; MacDermott, 2015).

In conclusion, assembling segments of synthetic DNA into long polynucleotide chains is a universal way

of obtaining compound heterozygous material that can then be used to perform any simultaneous analysis of polymorphic sites in the human genome. The batches are manufactured with a perfect concentration match of wild-type and mutant fragments, and can be made in large quantities and in lengths suitable for most diagnostic techniques.

Acknowledgement

Authors' conflict of interest disclosure: None declared.

References

- Almoguera, B., Vazquez, L., Connolly, J. J., Bradfield, J., Sleiman, P., Keating, B., Hakonarson, H. (2014) Imputation of *TPMT* defective alleles for the identification of patients with high-risk phenotypes. *Front. Genet.* **5**, 1-7.
- Ameyaw, M. M., Collie-Duguid, E. S., Powrie, R. H., Ofori-Adjei, D., McLeod, H. L. (1999) Thiopurine methyltransferase alleles in British and Ghanaian populations. *Hum. Mol. Genet.* **8**, 367-370.
- Beránek, M., Drastíková, M., Dulíček, P., Palička, V. (2014) Preparing compound heterozygous reference material using gene synthesis technology: a model of thrombophilic mutations. *Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.* **158**, 539-543.
- Burchard, P. R., Abou Tayoun, A. N., Lefferts, J. A., Lewis, L. D., Tsongalis, G. J., Cervinski, M. A. (2014) Development of a rapid clinical *TPMT* genotyping assay. *Clin. Biochem.* **47**, 126-129.
- Chen, D., Yang, Z., Xia, H., Huang, J. F., Zhang, Y., Jiang, T. N., Wang, G. Y., Chuai, Z. R., Fu, W.L., Huang, Q. (2014) Enhanced specificity of *TPMT*2* genotyping using unidirectional wild-type and mutant allele-specific scorpion primers in a single tube. *PLoS One* **9**, e91824.
- Fakhoury, M., Andreu-Gallien, J., Mahr, A., Medard, Y., Azougagh, S., Vilmer, E., Jacqz-Aigrain, E. (2007) Should *TPMT* genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? *J. Clin. Pharm. Ther.* **32**, 633-639.
- Geary, R. B., Barclay, M. L. (2005) Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. *J. Gastroenterol. Hepatol.* **20**, 1149-1157.
- Haglund, S., Lindqvist, M., Almer, S., Peterson, C., Taipalensuu, J. (2004) Pyrosequencing of *TPMT* alleles in a general Swedish population and in patients with inflammatory bowel disease. *Clin. Chem.* **50**, 288-295.
- Hughes, R. A., Miklos, A. E., Ellington, A. D. (2011) Gene synthesis: methods and applications. *Methods Enzymol.* **498**, 277-309.
- Krynetski, E. Y., Evans, W. E. (1999) Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. *Pharm. Res.* **16**, 342-349.
- MacDermott, R. P. (2015) 6-mercaptopurine (6-MP) metabolite monitoring and *TPMT* testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine. UpToDate on line [Electronic version]. Available at: <http://>

- www.uptodate.com/contents/6-mercaptopurine-6-mp-metabolite-monitoring-and-tpmt-testing-in-the-treatment-of-inflammatory-bowel-disease-with-6-mp-or-azathioprine.
- Pozler, O., Chládek, J., Malý, J., Hroch, M., Dědek, P., Beránek, M., Krásničanová, P. (2010) Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. *J. Crohns Colitis* **4**, 623-628.
- Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., Stein, C. M., Carrillo, M., Evans, W. E., Hicks, J. K., Schwab, M., Klein, T. E. (2013) Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. *Clin. Pharmacol. Ther.* **93**, 324-325.
- Roberts, R. L., Barclay, M. L., Gearry, R. B., Kennedy, M. A. (2004) A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. *Clin. Chim. Acta* **341**, 49-53.
- Roman, M., Cabaleiro, T., Ochoa, D., Novalbos, J., Chaparro, M., Gisbert, J. P., Abad-Santos, F. (2012) Validation of a genotyping method for analysis of TPMT polymorphisms. *Clin. Ther.* **34**, 878-884.
- Schutz, E., von Ahsen, N., Oellerich, M. (2000) Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, "two-color/shared" anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. *Clin. Chem.* **46**, 1728-1737.
- Soltysova, A., Minarik, G., Dzurenkova, A., Sufliarska, S., Kadasi, L., Turna, J., Mladosievicova, B. (2011) APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population. *Pharmacogenomics* **12**, 577-592.
- Spire-Vayron de la Moureyre, C., Debuysere, H., Mastain, B., Vinner, E., Marez, D., Lo Guidice, J. M., Chevalier, D., Brique, S., Motte, K., Colombel, J. F., Turck, D., Noel, C., Flipo, R. M., Pol, A., Lhermitte, M., Lafitte, J. J., Libersa, C., Broly, F. (1998a) Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. *Br. J. Pharmacol.* **125**, 879-887.
- Spire-Vayron de la Moureyre, C., Debuysere, H., Sabbagh, N., Marez, D., Vinner, E., Chevalier, E. D., Lo Guidice, J. M., Broly, F. (1998b) Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. *Hum. Mutat.* **12**, 177-185.
- Tai, H. L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., Evans, W. E. (1997) Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. *Proc. Natl. Acad. Sci. USA* **94**, 6444-6449.
- Yates, C. R., Krynetski, E. Y., Loennechen, T., Fessing, M. Y., Tai, H. L., Pui, C. H., Relling, M. V., Evans, W. E. (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. *Ann. Intern. Med.* **126**, 608-614.
- Zhou, S. F., Chowbay, B. (2007) Clinical significance of thiopurine S-methyltransferase gene polymorphisms. *Curr. Pharmacogenomics* **5**, 103-115.